What's new

Orphan designation: humanised IgG1 monoclonal antibody against muscle specific kinase Treatment of spinal muscular atrophy, 16/04/2025 Positive

Orphan designation: humanised IgG1 monoclonal antibody against muscle specific kinase Treatment of spinal muscular atrophy, 16/04/2025 Positive

Jun 5, 2025 - 15:00
 0
Orphan designation: humanised IgG1 monoclonal antibody against muscle specific kinase Treatment of spinal muscular atrophy, 16/04/2025 Positive
Orphan designation: humanised IgG1 monoclonal antibody against muscle specific kinase Treatment of spinal muscular atrophy, 16/04/2025 Positive
Read More

Tags:

Previous Article

Orphan designation: small-interfering RNA against soluble fms-like tyrosine kina...

Next Article

Orphan designation: vamikibart Treatment of non-infectious uveitis, 16/04/2025 P...

Related Posts

Orphan designation: vamikibart Treatment of non-infectious uveitis, 16/04/2025 Positive

Orphan designation: vamikibart Treatment of non-infecti...

Jun 5, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Spevigo, Spesolimab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0157/2024

Opinion/decision on a Paediatric investigation plan (PI...

Jun 6, 2025  0

Human medicines European public assessment report (EPAR): Absimky, ustekinumab, Date of authorisation: 12/12/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025  0